Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments.
J Clin Microbiol
; 43(10): 5214-20, 2005 Oct.
Article
em En
| MEDLINE
| ID: mdl-16207986
ABSTRACT
Detection of Aspergillus galactomannan (GM) in serum with the Platelia Aspergillus enzyme immunoassay (EIA) is useful for diagnosing invasive aspergillosis. From May 2003 to November 2004, 65 patients who did not develop aspergillosis had at least two positive sera while receiving a beta-lactam treatment (GM index [GMI], >or=0.5). Of the 69 treatment episodes scored, 41 consisted of a beta-lactam other than piperacillin-tazobactam (n=29), namely, amoxicillin-clavulanate (n=25), amoxicillin (n=10), ampicillin (n=3), or phenoxymethylpenicillin (n=2). In all cases, antigenemia became negative 24 h to 120 h upon stopping the antibiotic. Monitoring of 35 patients, including 26 with hematological malignancies, revealed three antigenemia kinetic patterns each was observed with any drug regimen and consisted of a persistent GMI of >2.0 (65.7%), >0.5, and
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Aspergillus
/
Fungemia
/
Beta-Lactamas
/
Mananas
/
Antígenos de Fungos
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
J Clin Microbiol
Ano de publicação:
2005
Tipo de documento:
Article
País de afiliação:
França